PubRank

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Clinical Trial ID NCT03791476

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03791476

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010 10.37
2 How dying cells alert the immune system to danger. Nat Rev Immunol 2008 8.63
3 Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 8.09
4 Ischemia and reperfusion--from mechanism to translation. Nat Med 2011 6.64
5 Complement regulators and inhibitory proteins. Nat Rev Immunol 2009 4.46
6 A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation 2009 4.45
7 Role of C5a in inflammatory responses. Annu Rev Immunol 2005 4.38
8 Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005 4.16
9 Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008 3.93
10 Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006 3.58
11 Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996 2.67
12 Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010 2.66
13 Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000 2.45
14 Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004 2.42
15 Inflammatory cells in ischemic acute renal failure. Kidney Int 2004 2.20
16 Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol (1985) 1999 2.13
17 Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013 2.10
18 Factor H family proteins and human diseases. Trends Immunol 2008 2.02
19 Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011 1.98
20 Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998 1.78
21 Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003 1.71
22 Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001 1.70
23 Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant 2014 1.61
24 Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 2004 1.61
25 Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2011 1.58
26 Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010 1.57
27 C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation 2014 1.49
28 Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 2005 1.44
29 Early activation of the inflammatory response in the liver of brain-dead non-human primates. J Surg Res 2011 1.40
30 Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009 1.36
31 The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004 1.28
32 Biological effects of C1 inhibitor. Drug News Perspect 2004 1.17
33 Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009 1.16
34 Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol 2010 1.12
35 In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol 2000 1.12
36 Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int 2003 1.10
37 C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010 1.09
38 Complement in organ transplantation. Curr Opin Organ Transplant 2010 1.08
39 The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991 1.08
40 Complement fragments C3a and C5a: the salt and pepper of the immune response. Eur J Immunol 2010 1.07
41 Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 1996 1.05
42 C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012 1.05
43 Effects of brain death on organ quality and transplant outcome. Transplant Rev (Orlando) 2012 1.02
44 Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant 2005 0.98
45 Complement and renal transplantation: from donor to recipient. Transplantation 2008 0.97
46 Effect of delayed graft function on short- and long-term kidney graft survival. Clin Transpl 1997 0.95
47 Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007 0.95
48 Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant 2010 0.93
49 The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984 0.90
50 Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant 2011 0.90
51 Risk factors for prolonged hospitalization after kidney transplants. Clin Transplant 1997 0.90
52 Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol 2006 0.89
53 Targeting complement activation in brain-dead donors improves renal function after transplantation. Transpl Immunol 2011 0.89
54 Impact of innate and adaptive immunity on rejection and tolerance. Transplantation 2008 0.89
55 Intragraft gene expression in positive crossmatch kidney allografts: ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012 0.87
56 Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994 0.87
57 Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. Clin J Am Soc Nephrol 2012 0.86
58 Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol 2000 0.86
59 Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013 0.86
60 Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol Immunol 2011 0.84
61 A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant 2008 0.83
62 Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int 2013 0.82
63 Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res 2009 0.82
64 Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation 2013 0.81
65 Brain death induced renal injury. Curr Opin Organ Transplant 2011 0.80
66 Kidney ischemic injury genes expressed after donor brain death are predictive for the outcome of kidney transplantation. Transplant Proc 2011 0.78
67 The complement cascade in kidney disease: from sideline to center stage. Am J Kidney Dis 2013 0.77
68 Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema. World Allergy Organ J 2010 0.76
69 The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation. Transplant Proc 2004 0.75
Next 100